20250001809196June 30, 2025falseQ2December 310001809196imtx:ShorttermDepositsMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2024-12-310001809196imtx:GeneralAndAdministrativeExpensesMember2024-01-012024-06-300001809196country:DKimtx:GenmabCollaborationAgreementMember2024-04-012024-06-300001809196imtx:ShorttermDepositsMember2025-06-300001809196imtx:ResearchAndDevelopmentExpensesMember2024-04-012024-06-300001809196ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2024-12-310001809196imtx:PerformanceBasedOptionsMember2024-12-310001809196imtx:GenmabCollaborationAgreementMember2024-01-012024-06-300001809196ifrs-full:SharePremiumMemberifrs-full:OrdinarySharesMember2025-01-012025-06-300001809196ifrs-full:IssuedCapitalMember2024-01-012024-06-300001809196country:USimtx:ModernaCollaborationAgreementMember2025-04-012025-06-300001809196imtx:MatchingStockOptionsMember2025-06-300001809196imtx:CollaborationAgreementsMember2024-04-012024-06-300001809196imtx:OfficeEquipmentAndInstallationsMember2025-01-012025-06-300001809196imtx:PerformanceBasedOptionsMember2025-04-012025-06-300001809196imtx:GrantedOnMarchTwoThousandAndTwentyOneMemberimtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember2025-01-012025-06-300001809196imtx:GeneralAndAdministrativeExpensesMember2024-04-012024-06-300001809196country:USimtx:BMSCollaborationAgreementMember2025-04-012025-06-300001809196ifrs-full:PreviouslyStatedMember2023-12-310001809196ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2024-12-310001809196country:DKimtx:GenmabCollaborationAgreementMember2025-01-012025-06-300001809196imtx:LiabilitiesForWarrantsMember2024-12-310001809196ifrs-full:OtherReservesMember2024-01-012024-06-300001809196ifrs-full:IssuedCapitalMemberifrs-full:OrdinarySharesMember2024-04-012024-06-300001809196imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember2025-06-300001809196imtx:GrantedOnFebruaryTwoThousandAndTwentyFourMemberimtx:PerformanceBasedOptionsMember2025-01-012025-06-300001809196ifrs-full:KeyManagementPersonnelOfEntityOrParentMember2025-04-012025-06-300001809196ifrs-full:TopOfRangeMember2024-03-310001809196ifrs-full:RetainedEarningsMember2024-12-3100018091962025-01-012025-03-310001809196imtx:ReorganizationMember2025-06-300001809196imtx:IFRS7NotApplicableAndIFRS16Member2025-06-300001809196imtx:RentalLandMember2025-01-012025-06-300001809196imtx:OfficeEquipmentAndInstallationsMember2024-04-012024-06-300001809196ifrs-full:SharePremiumMember2024-01-012024-06-3000018091962025-04-012025-06-300001809196imtx:BmsAndModernaCollaborationAgreementMember2024-04-012024-06-300001809196ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberimtx:AccountsPayablesMember2024-12-310001809196imtx:OfficeEquipmentAndInstallationsMember2024-01-012024-06-300001809196imtx:PublicOfferingMember2024-01-222024-01-220001809196imtx:ResearchAndDevelopmentExpensesMember2025-01-012025-06-300001809196ifrs-full:SharePremiumMemberifrs-full:OrdinarySharesMember2024-01-012024-06-300001809196ifrs-full:RetainedEarningsMember2024-06-300001809196ifrs-full:BottomOfRangeMember2025-03-310001809196ifrs-full:OtherReservesMember2024-06-300001809196ifrs-full:OtherReservesMember2023-12-310001809196ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2024-12-310001809196country:DKimtx:GenmabCollaborationAgreementMember2024-01-012024-06-300001809196ifrs-full:RetainedEarningsMember2023-12-310001809196imtx:OtherCurrentLiabilityMember2025-06-300001809196ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberimtx:LiabilitiesForWarrantsMember2024-12-3100018091962023-12-310001809196ifrs-full:TradeReceivablesMember2025-06-300001809196ifrs-full:MajorOrdinaryShareTransactionsMemberimtx:PublicOfferingMember2024-01-220001809196ifrs-full:IssuedCapitalMemberifrs-full:OrdinarySharesMember2025-01-012025-06-300001809196imtx:OtherCurrentLiabilityMember2024-12-310001809196imtx:RentalLandMember2024-04-012024-06-300001809196ifrs-full:SharePremiumMemberimtx:PublicOfferingMember2024-01-222024-01-220001809196imtx:CollaborationAgreementsMember2024-01-012024-06-300001809196imtx:AuthorizationOfFinancialStatementsMember2025-08-132025-08-130001809196country:USimtx:ModernaCollaborationAgreementMember2024-04-012024-06-300001809196imtx:OtherCurrentNonCurrentAssetsMember2025-06-300001809196ifrs-full:IssuedCapitalMember2024-12-310001809196country:DKimtx:GenmabCollaborationAgreementMember2025-04-012025-06-300001809196ifrs-full:SharePremiumMemberifrs-full:OrdinarySharesMember2024-04-012024-06-300001809196ifrs-full:OtherReservesMember2025-06-300001809196imtx:CashAndCashEquivalentMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2025-06-300001809196imtx:OfficeEquipmentAndInstallationsMember2025-04-012025-06-3000018091962025-06-300001809196ifrs-full:OtherReservesMember2024-12-310001809196ifrs-full:PreviouslyStatedMember2024-04-012024-06-300001809196imtx:IFRS7NotApplicableAndIFRS16Memberifrs-full:LeaseLiabilitiesMember2025-06-300001809196ifrs-full:TradeReceivablesMember2024-12-310001809196ifrs-full:IssuedCapitalMember2024-06-300001809196country:USimtx:BMSCollaborationAgreementMember2024-04-012024-06-300001809196ifrs-full:BottomOfRangeMember2023-12-310001809196country:USimtx:ModernaCollaborationAgreementMember2024-01-012024-06-3000018091962024-01-012024-12-310001809196imtx:IFRS7NotApplicableAndIFRS16Memberimtx:OtherCurrentLiabilityMember2025-06-3000018091962024-04-012024-06-300001809196ifrs-full:IssuedCapitalMember2023-12-310001809196imtx:IFRS7NotApplicableAndIFRS16Memberimtx:OtherCurrentNonCurrentAssetsMember2025-06-300001809196ifrs-full:SharePremiumMember2024-06-300001809196imtx:AccountsPayablesMember2024-12-310001809196ifrs-full:RetainedEarningsMember2025-01-012025-06-300001809196ifrs-full:IssuedCapitalMemberimtx:PublicOfferingMember2024-01-222024-01-220001809196ifrs-full:IssuedCapitalMember2025-06-300001809196imtx:ConvertedOptionsMember2025-01-012025-06-300001809196ifrs-full:SharePremiumMember2024-12-310001809196ifrs-full:TradeReceivablesMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2025-06-300001809196ifrs-full:LeaseLiabilitiesMember2024-12-310001809196imtx:OtherCurrentNonCurrentAssetsMember2024-12-310001809196country:DE2025-01-012025-06-300001809196ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2025-06-3000018091962024-12-310001809196imtx:ShorttermDepositsMember2024-12-310001809196imtx:ShorttermDepositsMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2025-06-300001809196ifrs-full:SharePremiumMemberifrs-full:OrdinarySharesMember2025-04-012025-06-300001809196imtx:OtherCurrentNonCurrentAssetsMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2025-06-300001809196ifrs-full:LeaseLiabilitiesMember2025-06-300001809196ifrs-full:PreviouslyStatedMember2024-06-300001809196imtx:BMSCollaborationAgreementMember2025-04-012025-06-300001809196imtx:CollaborationAgreementsMember2025-01-012025-06-300001809196ifrs-full:IssuedCapitalMemberifrs-full:OrdinarySharesMember2025-04-012025-06-300001809196imtx:CashAndCashEquivalentMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2024-12-310001809196ifrs-full:SharePremiumMember2023-12-310001809196imtx:ModernaCollaborationAgreementMember2025-04-012025-06-300001809196imtx:IFRS7NotApplicableAndIFRS16Memberimtx:OtherCurrentNonCurrentAssetsMember2024-12-3100018091962024-01-012024-03-310001809196imtx:GeneralAndAdministrativeExpensesMember2025-01-012025-06-300001809196imtx:MatchingStockOptionsMember2025-01-012025-06-300001809196ifrs-full:FinancialEffectOfCorrectionsOfAccountingErrorsMember2024-04-012024-06-300001809196country:USimtx:BMSCollaborationAgreementMember2025-01-012025-06-300001809196country:USimtx:BMSCollaborationAgreementMember2024-01-012024-06-300001809196imtx:GeneralAndAdministrativeExpensesMember2025-04-012025-06-300001809196imtx:PerformanceBasedOptionsMemberimtx:TrancheOneMember2025-06-300001809196ifrs-full:OtherReservesMember2025-01-012025-06-3000018091962024-03-310001809196ifrs-full:TradeReceivablesMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2024-12-310001809196imtx:IFRS7NotApplicableAndIFRS16Memberifrs-full:LeaseLiabilitiesMember2024-12-310001809196imtx:ResearchAndDevelopmentExpensesMember2024-01-012024-06-3000018091962025-03-310001809196imtx:PerformanceBasedOptionsMemberimtx:TrancheThreeMember2025-06-300001809196ifrs-full:SharePremiumMember2025-06-300001809196ifrs-full:BottomOfRangeMember2024-12-310001809196ifrs-full:SharePremiumMember2025-01-012025-06-300001809196imtx:CashAndCashEquivalentMember2024-12-310001809196ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberimtx:OtherCurrentLiabilityMember2025-06-3000018091962024-06-300001809196imtx:ResearchAndDevelopmentExpensesMember2025-04-012025-06-300001809196imtx:CashAndCashEquivalentMember2025-06-300001809196imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember2024-12-310001809196imtx:RentalLandMember2025-04-012025-06-300001809196imtx:TradeTaxMemberimtx:ImmaticsBiotechnologiesGmbhMembercountry:DE2025-01-012025-06-300001809196country:DE2025-06-300001809196ifrs-full:KeyManagementPersonnelOfEntityOrParentMember2025-01-012025-06-300001809196imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember2025-04-012025-06-300001809196ifrs-full:MajorOrdinaryShareTransactionsMemberimtx:PublicOfferingMember2024-01-222024-01-220001809196imtx:OtherCurrentNonCurrentAssetsMemberifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2024-12-310001809196imtx:PerformanceBasedOptionsMember2025-06-3000018091962025-01-012025-06-300001809196ifrs-full:RetainedEarningsMember2025-06-300001809196imtx:IFRS7NotApplicableAndIFRS16Member2024-12-310001809196ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberimtx:AccountsPayablesMember2025-06-300001809196ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2025-06-300001809196ifrs-full:FinancialEffectOfCorrectionsOfAccountingErrorsMember2024-01-012024-06-300001809196imtx:ImmaticsBiotechnologiesGmbhMembercountry:DEimtx:CorporateTaxMember2025-01-012025-06-300001809196country:USimtx:ModernaCollaborationAgreementMember2025-01-012025-06-300001809196ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberimtx:OtherCurrentLiabilityMember2024-12-310001809196imtx:AdditionalGrantsUnderTwoThousandAndTwentyAndTwoThousandAndTwentyTwoPlanMember2025-01-012025-06-300001809196ifrs-full:TopOfRangeMember2024-06-300001809196ifrs-full:TopOfRangeMember2025-06-300001809196imtx:IFRS7NotApplicableAndIFRS16Memberimtx:OtherCurrentLiabilityMember2024-12-310001809196imtx:ModernaCollaborationAgreementMember2025-01-012025-06-300001809196imtx:RentalLandMember2024-01-012024-06-300001809196ifrs-full:IssuedCapitalMemberifrs-full:OrdinarySharesMember2024-01-012024-06-300001809196imtx:PerformanceBasedOptionsMember2025-01-012025-06-300001809196imtx:CollaborationAgreementsMember2025-04-012025-06-3000018091962024-01-012024-06-300001809196imtx:NonInterestBearingLiabilityMember2025-01-012025-06-300001809196ifrs-full:RetainedEarningsMember2024-01-012024-06-300001809196ifrs-full:PreviouslyStatedMember2024-01-012024-06-300001809196imtx:ReorganizationMember2024-12-310001809196imtx:PerformanceBasedOptionsMemberimtx:TrancheTwoMember2025-06-300001809196imtx:MatchingStockOptionsMember2024-12-310001809196imtx:AccountsPayablesMember2025-06-30iso4217:EURimtx:Segmentxbrli:pureimtx:Warrantsxbrli:sharesiso4217:EURiso4217:USDiso4217:EURxbrli:sharesutr:Yiso4217:USD
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
August 13, 2025
Commission File Number: 001-39363
IMMATICS N.V.
Paul-Ehrlich-Straße 15
72076 Tübingen, Federal Republic of Germany
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On August 13, 2025, Immatics N.V. (the “Company”) issued an interim report for the three- and six-month period ended June 30, 2025, which is attached hereto as Exhibit 99.1, and issued a press release announcing the second quarter 2025 financial results and business update for the Company, which is attached hereto as Exhibit 99.2. In addition, the Company made available an updated investor presentation. A copy of this presentation is attached hereto as Exhibit 99.3.
INCORPORATION BY REFERENCE
This Report on Form 6-K (other than Exhibit 99.2 and Exhibit 99.3 hereto) including Exhibit 99.1 hereto, shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Nos. 333-249408, 333-265820, 333-280935 and 333-288466) and the registration statements on Form F-3 (Registration Nos. 333-240260, 333-274218 and 333-286151) of Immatics N.V. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBITS
|
|
|
|
Exhibit Number |
Description |
|
|
99.1 |
Immatics N.V. interim report for the three- and six-month period ended June 30, 2025. |
|
|
99.2 |
Press release dated August 13, 2025. |
|
|
99.3 |
Corporate presentation dated August 13, 2025. |
|
|
101.INS |
Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document |
|
|
101.SCH |
Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents |
|
|
104 |
Cover page formatted as Inline XBRL and contained in Exhibit 101 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
IMMATICS N.V. |
|
|
|
|
Date: August 13, 2025 |
|
by: |
/s/ Harpreet Singh |
|
|
|
Harpreet Singh |
|
|
|
Chief Executive Officer |
